Report Detail

Pharma & Healthcare Global Opioid Induced Constipation (OIC) Drug Market Research Report 2019

  • RnM3116507
  • |
  • 03 August, 2020
  • |
  • Global
  • |
  • 150 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Opioid Induced Constipation (OIC) Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Opioid Induced Constipation (OIC) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Opioid Induced Constipation (OIC) Drug market is segmented into
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other

Segment by Application, the Opioid Induced Constipation (OIC) Drug market is segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional and Country-level Analysis
The Opioid Induced Constipation (OIC) Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Opioid Induced Constipation (OIC) Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Opioid Induced Constipation (OIC) Drug Market Share Analysis
Opioid Induced Constipation (OIC) Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Opioid Induced Constipation (OIC) Drug business, the date to enter into the Opioid Induced Constipation (OIC) Drug market, Opioid Induced Constipation (OIC) Drug product introduction, recent developments, etc.

The major vendors covered:
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals


1 Study Coverage

  • 1.1 Opioid Induced Constipation (OIC) Drug Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Opioid Induced Constipation (OIC) Drug Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Opioid Induced Constipation (OIC) Drug Market Size Growth Rate by Type
    • 1.4.2 Lubiprostone
    • 1.4.3 Methyl Naltrexone Bromide
    • 1.4.4 Naldemedine
    • 1.4.5 Alvimopan
    • 1.4.6 Other
  • 1.5 Market by Application
    • 1.5.1 Global Opioid Induced Constipation (OIC) Drug Market Size Growth Rate by Application
    • 1.5.2 Hospital Pharmacies
    • 1.5.3 Retail Pharmacies
    • 1.5.4 Online Pharmacies
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Opioid Induced Constipation (OIC) Drug Market Size, Estimates and Forecasts
    • 2.1.1 Global Opioid Induced Constipation (OIC) Drug Revenue 2015-2026
    • 2.1.2 Global Opioid Induced Constipation (OIC) Drug Sales 2015-2026
  • 2.2 Global Opioid Induced Constipation (OIC) Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Opioid Induced Constipation (OIC) Drug Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Opioid Induced Constipation (OIC) Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Opioid Induced Constipation (OIC) Drug Competitor Landscape by Players

  • 3.1 Opioid Induced Constipation (OIC) Drug Sales by Manufacturers
    • 3.1.1 Opioid Induced Constipation (OIC) Drug Sales by Manufacturers (2015-2020)
    • 3.1.2 Opioid Induced Constipation (OIC) Drug Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Opioid Induced Constipation (OIC) Drug Revenue by Manufacturers
    • 3.2.1 Opioid Induced Constipation (OIC) Drug Revenue by Manufacturers (2015-2020)
    • 3.2.2 Opioid Induced Constipation (OIC) Drug Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Opioid Induced Constipation (OIC) Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Opioid Induced Constipation (OIC) Drug Revenue in 2019
    • 3.2.5 Global Opioid Induced Constipation (OIC) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Opioid Induced Constipation (OIC) Drug Price by Manufacturers
  • 3.4 Opioid Induced Constipation (OIC) Drug Manufacturing Base Distribution, Product Types
    • 3.4.1 Opioid Induced Constipation (OIC) Drug Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Opioid Induced Constipation (OIC) Drug Product Type
    • 3.4.3 Date of International Manufacturers Enter into Opioid Induced Constipation (OIC) Drug Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Opioid Induced Constipation (OIC) Drug Market Size by Type (2015-2020)
    • 4.1.1 Global Opioid Induced Constipation (OIC) Drug Sales by Type (2015-2020)
    • 4.1.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Type (2015-2020)
    • 4.1.3 Opioid Induced Constipation (OIC) Drug Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Opioid Induced Constipation (OIC) Drug Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Type (2021-2026)
    • 4.2.3 Opioid Induced Constipation (OIC) Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Opioid Induced Constipation (OIC) Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Opioid Induced Constipation (OIC) Drug Market Size by Application (2015-2020)
    • 5.1.1 Global Opioid Induced Constipation (OIC) Drug Sales by Application (2015-2020)
    • 5.1.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Application (2015-2020)
    • 5.1.3 Opioid Induced Constipation (OIC) Drug Price by Application (2015-2020)
  • 5.2 Opioid Induced Constipation (OIC) Drug Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Opioid Induced Constipation (OIC) Drug Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Opioid Induced Constipation (OIC) Drug by Country
    • 6.1.1 North America Opioid Induced Constipation (OIC) Drug Sales by Country
    • 6.1.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Type
  • 6.3 North America Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Opioid Induced Constipation (OIC) Drug by Country
    • 7.1.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Country
    • 7.1.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Type
  • 7.3 Europe Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Opioid Induced Constipation (OIC) Drug by Region
    • 8.1.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Region
    • 8.1.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Type
  • 8.3 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Opioid Induced Constipation (OIC) Drug by Country
    • 9.1.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Country
    • 9.1.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Type
  • 9.3 Central & South America Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug by Country
    • 10.1.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country
    • 10.1.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Type
  • 10.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Ironwood Pharmaceuticals
    • 11.1.1 Ironwood Pharmaceuticals Corporation Information
    • 11.1.2 Ironwood Pharmaceuticals Description and Business Overview
    • 11.1.3 Ironwood Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.1.5 Ironwood Pharmaceuticals Related Developments
  • 11.2 Daiichi Sankyo Co
    • 11.2.1 Daiichi Sankyo Co Corporation Information
    • 11.2.2 Daiichi Sankyo Co Description and Business Overview
    • 11.2.3 Daiichi Sankyo Co Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.2.5 Daiichi Sankyo Co Related Developments
  • 11.3 Pfizer
    • 11.3.1 Pfizer Corporation Information
    • 11.3.2 Pfizer Description and Business Overview
    • 11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Pfizer Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.3.5 Pfizer Related Developments
  • 11.4 Progenics Pharmaceuticals
    • 11.4.1 Progenics Pharmaceuticals Corporation Information
    • 11.4.2 Progenics Pharmaceuticals Description and Business Overview
    • 11.4.3 Progenics Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.4.5 Progenics Pharmaceuticals Related Developments
  • 11.5 Shionogi &
    • 11.5.1 Shionogi & Corporation Information
    • 11.5.2 Shionogi & Description and Business Overview
    • 11.5.3 Shionogi & Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Shionogi & Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.5.5 Shionogi & Related Developments
  • 11.6 Allergan
    • 11.6.1 Allergan Corporation Information
    • 11.6.2 Allergan Description and Business Overview
    • 11.6.3 Allergan Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Allergan Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.6.5 Allergan Related Developments
  • 11.7 Nektar Therapeutics
    • 11.7.1 Nektar Therapeutics Corporation Information
    • 11.7.2 Nektar Therapeutics Description and Business Overview
    • 11.7.3 Nektar Therapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.7.5 Nektar Therapeutics Related Developments
  • 11.8 Purdue Pharma
    • 11.8.1 Purdue Pharma Corporation Information
    • 11.8.2 Purdue Pharma Description and Business Overview
    • 11.8.3 Purdue Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.8.5 Purdue Pharma Related Developments
  • 11.9 S.L.A. Pharma
    • 11.9.1 S.L.A. Pharma Corporation Information
    • 11.9.2 S.L.A. Pharma Description and Business Overview
    • 11.9.3 S.L.A. Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.9.5 S.L.A. Pharma Related Developments
  • 11.10 Mundipharma International Limited
    • 11.10.1 Mundipharma International Limited Corporation Information
    • 11.10.2 Mundipharma International Limited Description and Business Overview
    • 11.10.3 Mundipharma International Limited Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.10.5 Mundipharma International Limited Related Developments
  • 11.1 Ironwood Pharmaceuticals
    • 11.1.1 Ironwood Pharmaceuticals Corporation Information
    • 11.1.2 Ironwood Pharmaceuticals Description and Business Overview
    • 11.1.3 Ironwood Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered
    • 11.1.5 Ironwood Pharmaceuticals Related Developments
  • 11.12 Takeda Pharmaceutical Company Limited
    • 11.12.1 Takeda Pharmaceutical Company Limited Corporation Information
    • 11.12.2 Takeda Pharmaceutical Company Limited Description and Business Overview
    • 11.12.3 Takeda Pharmaceutical Company Limited Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Takeda Pharmaceutical Company Limited Products Offered
    • 11.12.5 Takeda Pharmaceutical Company Limited Related Developments
  • 11.13 Theravance Biopharma
    • 11.13.1 Theravance Biopharma Corporation Information
    • 11.13.2 Theravance Biopharma Description and Business Overview
    • 11.13.3 Theravance Biopharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Theravance Biopharma Products Offered
    • 11.13.5 Theravance Biopharma Related Developments
  • 11.14 Bausch Health
    • 11.14.1 Bausch Health Corporation Information
    • 11.14.2 Bausch Health Description and Business Overview
    • 11.14.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Bausch Health Products Offered
    • 11.14.5 Bausch Health Related Developments
  • 11.15 Cosmo Pharmaceuticals SA
    • 11.15.1 Cosmo Pharmaceuticals SA Corporation Information
    • 11.15.2 Cosmo Pharmaceuticals SA Description and Business Overview
    • 11.15.3 Cosmo Pharmaceuticals SA Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Cosmo Pharmaceuticals SA Products Offered
    • 11.15.5 Cosmo Pharmaceuticals SA Related Developments
  • 11.16 Daewoong Pharmaceutical
    • 11.16.1 Daewoong Pharmaceutical Corporation Information
    • 11.16.2 Daewoong Pharmaceutical Description and Business Overview
    • 11.16.3 Daewoong Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 Daewoong Pharmaceutical Products Offered
    • 11.16.5 Daewoong Pharmaceutical Related Developments
  • 11.17 C.B. Fleet Company
    • 11.17.1 C.B. Fleet Company Corporation Information
    • 11.17.2 C.B. Fleet Company Description and Business Overview
    • 11.17.3 C.B. Fleet Company Sales, Revenue and Gross Margin (2015-2020)
    • 11.17.4 C.B. Fleet Company Products Offered
    • 11.17.5 C.B. Fleet Company Related Developments
  • 11.18 Sucampo Pharmaceuticals
    • 11.18.1 Sucampo Pharmaceuticals Corporation Information
    • 11.18.2 Sucampo Pharmaceuticals Description and Business Overview
    • 11.18.3 Sucampo Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.18.4 Sucampo Pharmaceuticals Products Offered
    • 11.18.5 Sucampo Pharmaceuticals Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Opioid Induced Constipation (OIC) Drug Market Estimates and Projections by Region
    • 12.1.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Regions 2021-2026
  • 12.2 North America Opioid Induced Constipation (OIC) Drug Market Size Forecast (2021-2026)
    • 12.2.1 North America: Opioid Induced Constipation (OIC) Drug Sales Forecast (2021-2026)
    • 12.2.2 North America: Opioid Induced Constipation (OIC) Drug Revenue Forecast (2021-2026)
    • 12.2.3 North America: Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Opioid Induced Constipation (OIC) Drug Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Opioid Induced Constipation (OIC) Drug Sales Forecast (2021-2026)
    • 12.3.2 Europe: Opioid Induced Constipation (OIC) Drug Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Opioid Induced Constipation (OIC) Drug Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Opioid Induced Constipation (OIC) Drug Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Opioid Induced Constipation (OIC) Drug Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Opioid Induced Constipation (OIC) Drug Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Opioid Induced Constipation (OIC) Drug Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Opioid Induced Constipation (OIC) Drug Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Opioid Induced Constipation (OIC) Drug Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Opioid Induced Constipation (OIC) Drug Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Opioid Induced Constipation (OIC) Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Opioid Induced Constipation (OIC) Drug Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Summary:
    Get latest Market Research Reports on Opioid Induced Constipation (OIC) Drug . Industry analysis & Market Report on Opioid Induced Constipation (OIC) Drug is a syndicated market report, published as Global Opioid Induced Constipation (OIC) Drug Market Research Report 2019. It is complete Research Study and Industry Analysis of Opioid Induced Constipation (OIC) Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    3,014.70
    4,522.05
    6,029.40
    3,630.90
    5,446.35
    7,261.80
    595,491.00
    893,236.50
    1,190,982.00
    329,160.00
    493,740.00
    658,320.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report